All patients required immunosuppressive therapy. Methotrexate (MTX) was used in all of our patients. The rate of complete remission was ~60%. Although the recurrence rate after stopping MTX was 70%, these patients responded well see more to re-treatment with MTX. We believe that MTX represents an effective treatment option for EF. The rarity of this disease would make a double-blind
controlled trial study difficult to perform. “
“Open access publications are expensive for authors. It is, however, likely that open access papers may get cited more often due to higher visibility and hence an open access journal have the potential to improve impact factor. Many top rated journals, on the other hand, charge hefty fees too for authors as publication fees. Not all institutes support Belnacasan price author fees. This puts researchers from developing nations in tight spot leaving the low impact factor, non-open access journals as the only targets. Good work, therefore, may go unnoticed if it is not just a click away from the reader. Combined effect of low impact factor and high cost of accessing
publications from economically disadvantaged nations act like a two edged sword. High cost of publication by a reputed publisher is a reality. It is even higher if the readers seek a print version, often from the developing world. Benefits of Hinari from WHO is also being narrowed down to fewer nations. Who should then pay for access to science by clinicians and researchers of the Developing world? Authors, readers, libraries, organizations or the industry? Can anyone find the Good Samaritan? “
“Difficulty in finding a patient of RA with advanced and classical deformities in hand for undergraduate and postgraduate teaching is a common experience of all rheumatologists in recent years. Thanks to the RA revolution in the last 2 decades Mirabegron which came after a period
of lull following the introduction of magical methotrexate in eighties. It is not newer medications alone; conceptualisation of the entity of early or preclinical RA and its recognition by new diagnostic armamentarium like anti citrullinated peptide antibody (ACPA), musculoskeletal ultrasonography and peripheral/extremity MRI, introduction of multiple sensitive and user friendly composite disease assessment tools like DAS28 and C-DAI, new ACR_EULAR classification criteria and above all, the recent concept of ‘treat to target’ (‘T2T’) made no lesser contributions. Dramatic entry of biologics starting with TNF blockers gave the momentum in late nineties and there was no going back since then. Whole range of them came out targeting B cells (Rituximab), co-stimulatory pathways (Abatacept), IL-6 (Tocilizumab), IL-1 (Anakinra) and now the small molecules or oral biologics (Tofacitinib). And the process is on targeting different other cytokine pathways. A shortlived journey with coxibs during the same period goes down the memory lane as another exciting pastime.